Michele Dowless
Overview
Explore the profile of Michele Dowless including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
524
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schubert N, Chen C, Rodriguez A, Koster J, Dowless M, Pfister S, et al.
Eur J Cancer
. 2022 Jun;
170:196-208.
PMID: 35671543
Background: Childhood cancer is still a leading cause of death around the world. To improve outcomes, there is an urgent need for tailored treatment. The systematic evaluation of existing preclinical...
2.
Lowery C, Blosser W, Dowless M, Renschler M, Perez L, Stephens J, et al.
Oncotarget
. 2019 Oct;
10(53):5523-5533.
PMID: 31565186
Vascular endothelial growth factor receptor 2 (VEGFR2) is an attractive therapeutic target in solid malignancies due to its central role in tumor angiogenesis. Ramucirumab (Cyramza, LY3009806) is a human monoclonal...
3.
Lowery C, Dowless M, Renschler M, Blosser W, VanWye A, Stephens J, et al.
Clin Cancer Res
. 2018 Dec;
25(7):2278-2289.
PMID: 30563935
Purpose: Checkpoint kinase 1 (CHK1) inhibitors potentiate the DNA-damaging effects of cytotoxic therapies and/or promote elevated levels of replication stress, leading to tumor cell death. Prexasertib (LY2606368) is a CHK1...
4.
Gong X, Du J, Parsons S, Merzoug F, Webster Y, Iversen P, et al.
Cancer Discov
. 2018 Oct;
9(2):248-263.
PMID: 30373917
Loss-of-function mutations in the retinoblastoma gene are common in several treatment-refractory cancers such as small-cell lung cancer and triple-negative breast cancer. To identify drugs synthetic lethal with mutation ( ),...
5.
Dowless M, Lowery C, Shackleford T, Renschler M, Stephens J, Flack R, et al.
Clin Cancer Res
. 2018 Aug;
24(23):6028-6039.
PMID: 30131386
Purpose: Ewing sarcoma (ES) is a rare and highly malignant cancer that occurs in the bone and surrounding tissue of children and adolescents. The fusion transcription factor that drives ES...
6.
Gong X, Litchfield L, Webster Y, Chio L, Wong S, Stewart T, et al.
Cancer Cell
. 2017 Dec;
32(6):761-776.e6.
PMID: 29232554
Most cancers preserve functional retinoblastoma (Rb) and may, therefore, respond to inhibition of D-cyclin-dependent Rb kinases, CDK4 and CDK6. To date, CDK4/6 inhibitors have shown promising clinical activity in breast...
7.
Lowery C, Blosser W, Dowless M, Knoche S, Stephens J, Li H, et al.
Clin Cancer Res
. 2017 Dec;
24(4):847-857.
PMID: 29191969
Platelet-derived growth factor receptor α (PDGFRα) is implicated in several adult and pediatric malignancies, where activated signaling in tumor cells and/or cells within the microenvironment drive tumorigenesis and disease progression....
8.
Lowery C, VanWye A, Dowless M, Blosser W, Falcon B, Stewart J, et al.
Clin Cancer Res
. 2017 Mar;
23(15):4354-4363.
PMID: 28270495
Checkpoint kinase 1 (CHK1) is a key regulator of the DNA damage response and a mediator of replication stress through modulation of replication fork licensing and activation of S and...
9.
Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan X, et al.
Oncotarget
. 2016 Dec;
8(6):9251-9266.
PMID: 27999210
Activating mutations in the KRAS and BRAF genes, leading to hyperactivation of the RAS/RAF/MAPK oncogenic signaling cascade, are common in patients with colorectal cancer (CRC). While selective BRAF inhibitors are...
10.
Peng S, Zhang X, Paul D, Kays L, Ye M, Vaillancourt P, et al.
PLoS One
. 2016 Mar;
11(3):e0150585.
PMID: 26954567
SDF-1 and CXCR4 are a chemokine and chemokine receptor pair playing critical roles in tumorigenesis. Overexpression of CXCR4 is a hallmark of many hematological malignancies including acute myeloid leukemia, chronic...